broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-M97302542-001-04-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.7731 | 1.693968 | 0.221352 | 0.874601 | 0.046836 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000911 |
BRD-A25234499-001-19-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.005097 | -0.174068 | -0.065499 | 1 | 0.021615 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000913 |
BRD-A74914197-001-02-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.466291 | 0.022246 | 0.002947 | 1 | 0.31592 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000913 |
BRD-K02113016-001-19-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.699726 | 1.910245 | 0.21394 | 0.868796 | 0.144036 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000913 |
BRD-K02130563-001-11-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.216002 | 4.427679 | 0.82393 | 0.763698 | 0.536625 | 0.609751 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000913 |
BRD-K03390685-001-01-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.176599 | 1.377649 | 0.192858 | 1 | 0.220518 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000913 |
BRD-K03406345-001-21-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.727175 | -0.337057 | -0.032608 | 0.893396 | 0.015859 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000913 |
BRD-K03449891-001-08-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.414101 | 0.499118 | 0.449536 | 0.791618 | 0.189049 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000913 |
BRD-K03765900-001-01-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.278463 | 3.879624 | 0.899014 | 0.816077 | 0.842686 | 1.039416 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000913 |
BRD-K05804044-001-18-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 140.549431 | -6.601864 | -0.023655 | 1 | 0.000084 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000913 |
BRD-K06814349-304-02-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.500446 | 1.407435 | 0.591762 | 1 | 0.098906 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000913 |
BRD-K08109215-001-06-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.87102 | 9.46872 | -0.196868 | 0.954205 | 0.31884 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000913 |
BRD-K08542803-001-02-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.167415 | 9.404323 | 0.755386 | 0.681661 | 0.244635 | 0.255479 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000913 |
BRD-K08547377-001-04-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.278227 | 4.072936 | 0.876254 | 0.471552 | 0.008208 | 0.010021 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000913 |
BRD-K08703257-001-13-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 22.27787 | 0.420887 | -0.00365 | 1 | 1,070,164,166,395,977.2 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000913 |
BRD-K08799216-001-05-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.804849 | 0.837468 | -0.238629 | 0.910733 | 0.119815 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000913 |
BRD-K09951645-001-11-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.352985 | 0.63936 | 0.030383 | 1 | 2.808247 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000913 |
BRD-K11267252-001-05-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.100707 | -0.027058 | -0.000194 | 1 | 0.003599 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000913 |
BRD-K11630072-001-13-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.2888 | 1.586247 | 0.283322 | 1 | 0.031199 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000913 |
BRD-K12184916-001-19-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.466192 | 0.511782 | 0.040645 | 0.621695 | 0.0063 | 1.217117 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000913 |
BRD-K12343256-001-14-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.413126 | 1.011913 | 0.273622 | 1 | 0.069184 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000913 |
BRD-K13049116-001-04-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.320953 | 2.325905 | 0.906865 | 0.847263 | 1.130249 | 1.757647 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000913 |
BRD-K13390322-001-06-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.221328 | 5.795555 | 0.723668 | 0.74252 | 0.403975 | 0.446852 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000913 |
BRD-K13514097-001-04-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.296434 | -0.221905 | 0.336004 | 0.730226 | 0.007527 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000913 |
BRD-K13662825-001-07-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.234672 | 4.661655 | 0.48193 | 0.546665 | 0.007985 | 0.009147 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000913 |
BRD-K14109347-001-03-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.360058 | 337.492076 | 0.195953 | 0.981003 | 7.496983 | 7.52534 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000913 |
BRD-K15179879-001-03-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.314553 | 4.967928 | 0.721807 | 0.603032 | 0.036235 | 0.044242 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000913 |
BRD-K15600710-066-05-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.306307 | 3.49061 | 0.314492 | 0.739774 | 0.25763 | 0.338061 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000913 |
BRD-K17555800-003-02-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.776982 | 1.226091 | 0.009835 | 0.894003 | 0.099401 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000913 |
BRD-K17610631-001-03-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.157732 | 0.396521 | 0.375845 | 0.605839 | 0.114853 | 0.298719 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000913 |
BRD-K17743125-001-08-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.026521 | 0.515671 | 0.213953 | 0.665833 | 0.487201 | 0.541513 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000913 |
BRD-K17894950-001-14-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.044349 | 0.762368 | -0.222147 | 1 | 0.001361 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000913 |
BRD-K18961567-001-01-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.586147 | -2.764838 | 0.222198 | 1 | 0.015042 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000913 |
BRD-K19540840-001-09-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.265314 | 4.902677 | 0.78332 | 0.772174 | 0.493206 | 0.575479 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000913 |
BRD-K19687926-001-04-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.949364 | 1.427229 | 0.04499 | 0.968094 | 0.022007 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000913 |
BRD-K19796430-001-05-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.68021 | -3.59104 | 0.437761 | 1 | 0.003316 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000913 |
BRD-K22064724-001-01-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.19218 | 3.127086 | 0.624165 | 0.690884 | 0.243914 | 0.284849 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000913 |
BRD-K22822991-001-02-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.968498 | 0.822753 | 0.016153 | 0.975021 | 0.003522 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000913 |
BRD-K23228615-001-02-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.400436 | 2.475285 | 0.645764 | 0.661312 | 0.041607 | 0.079858 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000913 |
BRD-K23984367-001-07-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.041139 | -0.218446 | -0.043194 | 1 | 4.548904 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000913 |
BRD-K26026438-001-01-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.251059 | -2.229102 | 0.162229 | 1 | 0.020488 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000913 |
BRD-K26657438-001-15-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.817279 | -1.126873 | 0.151571 | 0.957708 | 0.005358 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000913 |
BRD-K28822270-001-03-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.576804 | 0.617748 | 0.503796 | 0.827481 | 0.221362 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000913 |
BRD-K29905972-001-06-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.785155 | 0.185258 | -0.069713 | 0.894483 | 0.095797 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000913 |
BRD-K30577245-001-05-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.263925 | 1.709328 | 0.459441 | 0.758572 | 0.025972 | 0.040288 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000913 |
BRD-K31698212-001-02-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.780596 | 1.248416 | 0.051259 | 0.824327 | 0.003916 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000913 |
BRD-K31928526-001-02-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.849723 | 0.251745 | -0.099442 | 0.881007 | 0.000222 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000913 |
BRD-K33379087-001-07-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.538486 | 10.118785 | 0.364415 | 0.9011 | 1.249736 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000913 |
BRD-K33610132-001-02-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.384028 | 0.307603 | 0.048191 | 1 | 2.69102 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000913 |
BRD-K33622447-066-01-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.227749 | -0.170811 | -0.012444 | 1 | 0.116885 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000913 |
BRD-K35520305-001-16-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.198337 | -0.060178 | -0.124222 | 1 | 0.520812 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000913 |
BRD-K36627727-001-05-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.135946 | 0.345417 | -0.034029 | 1 | 0.000637 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000913 |
BRD-K36788280-001-01-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.85508 | -7.157094 | -0.076469 | 0.886985 | 1.180653 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000913 |
BRD-K37379014-001-02-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.270754 | 0.749837 | 0.351804 | 0.69668 | 0.002888 | 0.008171 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000913 |
BRD-K38332599-001-01-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.601897 | 8.13921 | 0.475963 | 0.745193 | 0.020063 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000913 |
BRD-K38527262-300-01-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.207078 | 0.480189 | 0.381571 | 0.743267 | 0.61097 | 1.860441 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000913 |
BRD-K38852836-001-02-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.481839 | 1.897331 | 0.058059 | 0.870563 | 0.222732 | 1.278353 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000913 |
BRD-K39974922-001-04-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.628418 | 2.182528 | 0.18421 | 0.805982 | 0.063001 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000913 |
BRD-K41859756-001-06-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.711843 | 10.796584 | 0.077819 | 0.816219 | 0.005138 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000913 |
BRD-K42495768-001-01-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.539128 | 5.616838 | 0.395091 | 0.933362 | 2.45826 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000913 |
BRD-K42805893-001-04-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.764812 | 0.293575 | 0.009898 | 0.86362 | 0.021809 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000913 |
BRD-K42828737-001-03-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.090523 | 0.233923 | -0.038979 | 1 | 0.003017 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000913 |
BRD-K42898655-001-01-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.324354 | -0.090987 | 0.036021 | 0.661189 | 0.005209 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000913 |
BRD-K43389675-001-02-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.234922 | 3.42264 | 0.719634 | 0.584374 | 0.051332 | 0.061789 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000913 |
BRD-K44227013-001-06-4 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.301473 | 1.921728 | 0.658649 | 0.727481 | 0.226917 | 0.366954 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000913 |
BRD-K44408410-001-17-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | -2.192283 | 2.672308 | 0.47038 | 0.973074 | 16.93968 | 9.022103 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000913 |
BRD-K44827188-001-06-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.790196 | 3.74972 | 0.121917 | 0.916082 | 0.206158 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000913 |
BRD-K46386702-001-02-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.598879 | -0.01674 | -0.011779 | 0.813995 | 0.000013 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000913 |
BRD-K49328571-001-15-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.100927 | 0.293898 | 0.467799 | 0.35309 | 0.001945 | 0.004189 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000913 |
BRD-K49350383-001-14-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.373849 | -0.007573 | -0.001241 | 1 | 13,566,782,179,293,375,000,000 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000913 |
BRD-K50010139-001-01-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.495111 | 0.123884 | -0.084321 | 0.703916 | 0.004286 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000913 |
BRD-K50168500-001-07-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.307667 | 5.770062 | 0.357852 | 0.961336 | 5.861385 | 6.916853 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000913 |
BRD-K51313569-001-07-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.739834 | -0.793405 | -0.140631 | 0.950774 | 0.002746 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000913 |
BRD-K51791723-003-01-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.198248 | 0.531718 | 0.493756 | 0.719797 | 0.441647 | 1.14169 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000913 |
BRD-K51967704-001-03-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.941008 | 1.400933 | -0.088026 | 0.959467 | 0.012582 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000913 |
BRD-K52313696-001-12-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.835278 | 0.219971 | 0.012253 | 0.885816 | 0.001386 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000913 |
BRD-K53414658-001-08-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.568124 | 2.421262 | 0.373167 | 0.890897 | 0.862466 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000913 |
BRD-K53972329-001-07-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.905077 | -3.535866 | 0.017512 | 0.945379 | 0.162393 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000913 |
BRD-K54256913-001-08-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.235234 | 1.631672 | 0.610394 | 0.770504 | 0.546437 | 0.80679 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000913 |
BRD-K54955827-001-02-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.586882 | 0.725097 | 0.372548 | 0.775897 | 0.050416 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000913 |
BRD-K54997624-001-06-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.368221 | 3.030024 | 0.668227 | 0.789256 | 0.392746 | 0.609867 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000913 |
BRD-K55187425-236-05-2 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.230241 | 0.676076 | 0.255688 | 0.675987 | 0.179189 | 0.446383 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000913 |
BRD-K56343971-001-14-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.34193 | 3.425841 | 0.285206 | 1 | 0.09106 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000913 |
BRD-K56981171-001-02-8 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.476739 | 1.508218 | 0.557277 | 0.87788 | 1.061658 | 8.116616 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000913 |
BRD-K57080016-001-15-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.908992 | -2.96785 | 0.287239 | 0.958769 | 0.049517 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000913 |
BRD-K57169635-001-04-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.601138 | 0.108888 | 0.028202 | 0.810166 | 0.193062 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000913 |
BRD-K58435339-001-03-0 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.838688 | 0.64891 | -0.149406 | 0.931893 | 0.178364 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000913 |
BRD-K58529924-001-01-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.672463 | 1.056699 | -0.016282 | 0.855219 | 0.146347 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000913 |
BRD-K58550667-001-08-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.349658 | 5.127549 | 0.456221 | 0.875687 | 0.097768 | 0.123589 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000913 |
BRD-K59317601-001-05-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.429108 | 2.251802 | 0.589329 | 0.57965 | 0.007873 | 0.018744 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000913 |
BRD-K59369769-001-22-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.719493 | -5.901654 | -0.012965 | 0.799813 | 0.621112 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000913 |
BRD-K60866521-001-07-1 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.731234 | -1.225392 | -0.007009 | 0.957438 | 0.002479 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000913 |
BRD-K60997853-001-02-3 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.265649 | 1.246445 | 0.579799 | 0.782693 | 0.578887 | 1.063233 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000913 |
BRD-K61192372-001-08-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.061468 | -0.467686 | -0.009733 | 1 | 0.016368 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000913 |
BRD-K62008436-001-23-9 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.343135 | 3.736563 | 0.683581 | 0.69642 | 0.007045 | 0.009607 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000913 |
BRD-K62196610-001-01-6 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.06828 | 0.21109 | -0.015294 | 1 | 0.003437 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000913 |
BRD-K62200014-003-10-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.69801 | 1.589003 | 0.014142 | 0.860801 | 0.114141 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000913 |
BRD-K62391742-001-09-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 0.70077 | 1.913269 | 0.29774 | 0.792329 | 0.011862 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000913 |
BRD-K62627508-001-01-5 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.350672 | 0.002514 | -0.034093 | 1 | 580,139,139,041,848,850,000,000,000,000,000,000,000,000,000 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000913 |
BRD-K63504947-001-14-7 | ACH-000913 | ESS1_ENDOMETRIUM | MTS010 | 1 | 1.477588 | -0.523881 | -0.215109 | 1 | 0.34605 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000913 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.